🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

83 results for “KS” Clear

  1. 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Seizure

    phase 3 small molecule active

    1 trial

  2. 40 mg/day vormatrogine for 12 weeks

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  3. ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia

    phase 3 small molecule active

    1 trial

  4. ALKS 9072

    Alkermes Pharma Ireland

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  5. ALKS 9072, Low Dose

    Alkermes Pharma Ireland

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  6. Apremilast, Apremilast, Apremilast

    Amgen

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  7. Budesonida Aldo-Unión 0,5 mg/ml suspensión para inhalación por nebulizador, CUROSURF® 120mg/vial + 240mg/vial Endotracheopulmonary Instillation Suspension

    The George Institute

    Bronchopulmonary dysplasia, Preterm newborns ≤32 weeks of gestational age.

    phase 3 small molecule active

    1 trial

  8. CEFTRIAXONE, AMOXICILLIN, AZITHROMYCIN

    Pari Pharma GmbH

    Population of study participants Pregnant women with PPROM at 22 to 33 weeks’ gestation

    phase 3 small molecule active

    1 trial

  9. Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pediatric Hereditary Kidney Diseases

    phase 3 small molecule active

    1 trial

  10. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, C1-esterase inhibitor

    Maze Therapeutics

    acute hereditary angioedema attacks

    phase 3 small molecule active

    1 trial

  11. KPL-387

    Kiniksa Pharmaceuticals International, plc

    Pericarditis

    phase 3 small molecule active

    1 trial

  12. Matching placebo for Tezepelumab solution for injection, TEZEPELUMAB

    AstraZeneca AB

    Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments

    phase 3 small molecule active

    1 trial

  13. Natriumklorid B. Braun 9 mg/ml infusjonsvæske, oppløsning, BOTOX 50 Allergan-enheter Pulver til injeksjonsvæske, oppløsning

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic cluster headache

    phase 3 small molecule active

    1 trial

  14. Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease

    Chiesi Farmaceutici S.p.A

    Fabry disease (α-galactosidase A deficiency)

    phase 3 other active

    1 trial

  15. Rilonacept

    Kiniksa Pharmaceuticals International, plc

    Recurrent Pericarditis

    phase 3 small molecule completed

    1 trial

  16. Sibeprenlimab 400 mg s.c. Q4weeks

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  17. TOPOTECAN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NEMVALEUKIN ALFA, GEMCITABINE HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  18. TachoSil®

    Takeda

    Cerebrospinal Fluid Leaks

    phase 3 other completed

    1 trial

  19. Tovorafenib, VINCRISIN 1 mg/ml solution injectable, 2 mg, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tovorafenib, VELBE 10 mg Trockensubstanz zur Injektionsbereitung, Vinblastin STADA 10 mg Pulver zur Herstellung einer Injektionslösung, cellcristin® 1 mg/ml Injektionslösung Wirkstoff: Vincristinsulfat, Vincristinesulfaat Teva 1 mg/ml, oplossing voor injectie, Vinblastinesulfaat 1 mg/ml PCH, oplossing voor injectie

    Lacuna Pharma Pty Ltd

    Pediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapy

    phase 3 small molecule active

    1 trial

  20. VIVITROL injection and VIVITROL Placebo Injection , 24 weeks

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine Dependence

    phase 3 small molecule completed

    1 trial

  21. [18F]-AlF-FAPI-74, GlucaGen®, HypoKit met 1 mg poeder en oplosmiddel voor oplossing voor injectie, Scopolamine butylbromide Kalceks 20 mg/ml oplossing voor injectie

    Disc Medicine

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  22. mavrilimumab

    Kiniksa Pharmaceuticals International, plc

    COVID

    phase 3 small molecule completed

    1 trial

  23. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  24. A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)

    Alphapharm Pty Ltd

    Congenital Hyperinsulinism (CHI)

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources